I think this all smells of a deal. Leo needs some shares at the ready to structure it just right. In fact, I believe the deal is specific for B.
Take a look at the company description from the last few press releases:
– Cellceutix Corporation (OTCQB: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications.
Now look at the "Our Company" description from the S-3, there is no mention of antibiotics and autism and inflammatory disease is added:
"We are a clinical stage developmental biotechnology pharmaceutical company focused on discovering small molecule drugs for hard to treat diseases, including drug-resistant cancers, psoriasis, autism and inflammatory disease"
CTIX can sell or partner b and focus on "autism and inflammatory disease".
My two cents! GO CTIX!!!!